BioSpace’s Post

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes "Conclusions and Relevance In this study, GLP-1RAs were associated with lower risks of specific types of OACs compared with insulins or metformin in patients with T2D. These findings provide preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies for the prevention of certain OACs." https://lnkd.in/eSeb5dHg

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes « In this study, GLP-1RAs were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients with T2D. These findings provide preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies for the prevention of certain obesity-associated cancers ». #GLP1 #cancer #publichealth #pharmacology #obesity https://lnkd.in/e-UrTp_w

Could GLP1 medications lower the risk of colon cancer? This retrospective study says yes Those on GLP1 meds had a 50% lower risk of colorectal cancer. Seems this is probably mostly related to weight loss and improvement and insulin resistance. Given that this is a retrospective study, it’s hard to know if this is cause and effect so further research is needed, but certainly promising American Diabetes Association #diabetes #diabetesmanagement #obesity #obesitytreatment #coloncancer https://lnkd.in/epQtAveq

Important analysis of 13 phase 3 lung cancer trials (n = 9,285) by FDA published in The Lancet concluding that the most common surrogate endpoints (i.e. response rate and progression-free survival) have only moderate ability to predict overall survival benefit in this setting. What this means for sponsors according to the authors: "Our findings also suggest that drug developers could miss opportunities to bring novel ICI-based therapies to the market by focusing solely on early clinical endpoints such as PFS, when the greater clinical benefit might be better demonstrated with an OS endpoint. The difference in median PFS between the experimental and control groups ranged from –1.7 months (favouring the control group) to 4.3 months, whereas the difference in median OS ranged from 1.2 months to 15.8 months. Had the design of some of these trials not formally tested overall survival, the overall risk–benefit assessment might not have been considered favourable."

The FDA has granted accelerated approval to Tarlatamab-dlle, a Bispecific T cell Engager (BiTE), for the treatment of recurrent/refractory extensive stage small cell lung cancer. Tarlatamab is a DLL3 and CD3 BiTE which showed promising efficacy (Objective Response Rate about 40%) and duration of response (9.7 months) in DeLLphi-301 trial. Certainly concerns for safety exist as there is high risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Nonetheless, this is a challenging disease, with not many second-line options available after progression on first-line chemo-immunotherapy, and high risk of progression in the CNS. While we continue to make strides in the field, we need treatments that have CNS activity. Will be awaiting for maturation of survival data. For interested readers, find the links below: https://lnkd.in/gCpQpUnM https://lnkd.in/gSmEYEam

In this study, GLP-1RAs were associated with lower risks of specific types (10 of 13) of obesity associated cancers (OACs) compared with insulins or metformin in patients with T2D. These findings provide preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies for the prevention of certain OACs.

Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers

GLP-1 RAs continue showing their therapeutic potential beyond obesity and diabetes, with a new study indicating that the drug class could significantly lower the risk of several cancers. The study, published Friday in JAMA Network Open, drew from the electronic health records of 113 million patients across the U.S., of whom nearly 1.7 million were taking GLP-1 analogs for type 2 diabetes. These patients had no history of obesity-associated cancers (OAC). As comparators, the researchers looked at patients who were treated with insulin. Over a 15-year period, GLP-1 RAs significantly lowered the risk of 10 out of the 13 OACs assessed in the study. These included gallbladder cancer, meningioma and pancreatic cancer, which were 65%, 63% and 59% less likely to develop than in insulin-treated counterparts, respectively. The risk of ovarian cancer was lowered by 48%, while that of hepatocellular carcinoma dropped by 53%. Colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer and kidney cancer were all also significantly less likely to arise in patients on GLP-1 RAs. #biotech #biopharma #pharma #cancer #GLP1 #obesity #weightloss

In a retrospective cohort study published in JAMA Network Open the researchers observed reduced risk for 10 out of 13 obesity-associated cancers, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancers, as well as meningioma and multiple myeloma, in type 2 diabetic (T2D) patients receiving GLP-1 receptor agonists (GLP-1RA) compared to those receiving insulin. No decrease in cancer risk was observed when comparing GLP-1RAs with metformin. Moreover, the study found a higher risk for kidney cancer in patients on GLP-1RAs versus metformin. Overall, these results highlight the potential cancer risk benefits of GLP-1RAs in high-risk populations. Note: The study did not specify which GLP-1 RA the patients received. https://lnkd.in/gXhBrgck

Global Renal Cancer Medication Market Report 2023-2028: